目的 观察苦参片联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床疗效。方法 选取2015年2月-2018年1月自贡市第一人民医院收治的溃疡性结肠炎患者116例作为研究对象，将所有患者随机分为对照组和治疗组，每组各58例。对照组患者口服美沙拉嗪肠溶片，2片/次，3次/d；治疗组在对照组治疗的基础上口服苦参片，4片/次，4次/d。两组患者均连续治疗90 d。观察两组患者的临床疗效，比较两组的炎症因子水平、临床症状改善时间和疾病活动指数（DAI）。结果 治疗后，对照组和治疗组的总有效率分别为72.41%、82.76%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组肿瘤坏死因子-α（TNF-α）、超敏C反蛋白（CRP）、白细胞介素-6（IL-6）和白细胞介素-8（IL-8）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组炎症因子水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组的黏液脓血便消失时间、腹泻症状恢复时间显著短于对照组（P<0.05）。治疗后，两组患者的DAI指数均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组DAI显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 苦参片联合美沙拉嗪肠溶片治疗溃疡性结肠炎具有较好的临床疗效，可显著改善患者临床症状，降低炎性反应，具有一定的临床推广使用价值。

Objective To investigate the clinical curative effect of Kushen Tablets combined with Mesalazine Enteric-Coated Tablets in treatment of ulcerative colitis. Methods Patients (116 cases) with ulcerative colitis in Zigong First People's Hospital from February 2015 to January 2018 were divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Mesalazine Enteric-Coated Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Kushen Tablets on the basis of control group, 4 tablets/time, four times daily. Patients in two groups were treated for 90 d. After treatment, the clinical efficacy were evaluated, and inflammatory factor levels, the clinical symptom improvement time, and DAI in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 72.41% and 82.76%, respectively, and there were differences between two groups (P < 0.05). After treatment, the TNF-α, CRP, IL-6, and IL-8 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, mucus abscess disappeared time and diarrhea symptoms recovery time in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, DAI in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, DAI in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Kushen Tablets combined with Mesalazine Enteric-Coated Tablets has clinical curative effect in treatment of ulcerative colitis, can improve the clinical symptoms, reduce inflammatory response, which has a certain clinical application value.